A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
A phase 2 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.
Overview
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU is a phase 2 interventional study registered as NCT05485948 by PharmaEssentia, with 49 participants enrolled, started 2021-10-08 and due to reach its primary completion in 2022-09-07. Interventions recorded: Ropeginterferon alfa-2b.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialRopeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialStudy to Assess SLN124 in Patients With Polycythemia Vera
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.